Lecture
This lecture covers the signaling dependencies of B-cell lymphomas and chronic lymphocytic leukemia, focusing on B-cell receptor pathways, transcription factors, and resistance mechanisms to BTK inhibitors. It also discusses drug resistance in the lab, melanoma examples, common genomic lesions, RAS/RAF and MAPK pathways, and the use of CRISPR/Cas9 for gene editing and CRISPR screens. Furthermore, it explores mTOR inhibitors, cell cycle inhibition, p53 restoration, proteasome/MDM2 inhibitors, synthetic lethality, and rational combination therapies. The lecture concludes with a discussion on undruggable oncogenes like RAS and MYC, clinical trials, and potential therapies for RAS and MYC-driven cancers.